NCT05545670View on ClinicalTrials.gov

Allopurinol to Prevent Cirrhosis Related Morbidities

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

February 15, 2023

Study Completion Date

March 1, 2023

Conditions
Cirrhosis
Interventions
DRUG

Placebo

not containing drugs

DRUG

Allopurinol 300 MG

a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation

Trial Locations (1)

31679

Faculty of Pharmacy, Tanta

All Listed Sponsors
lead

Tanta University

OTHER